Transcriptomic studies of mouse hippocampus (PRJCA047610)
This study aims to elucidate the transcriptomic mechanisms underlying the potential therapeutic effects of the novel compound 3r1 against Alzheimer's disease (AD)-like pathology. Utilizing the 5xFAD mouse model, a robust model of amyloidosis and AD-related neurodegeneration, we performed RNA-sequencing on hippocampal tissues following a three-month chronic administration of either 3r1 or a saline control. The primary goal is to identify genome-wide differential gene expression patterns, altered signaling pathways, and key biological processes modulated by 3r1 treatment. The relevance of this work lies in its potential to reveal the molecular targets and neuroprotective mechanisms of 3r1, thereby providing critical insights for its development as a promising therapeutic candidate for Alzheimer's disease.